Nadeem A Sheikh (Nadeem Sheikh)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 4

Top Topics

Drug Administration

Regulatory T Cells

Benign Prostatic Hyperplasia

Prostate Cancer

Top Venues

Cancer immunology research

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Muhammad A Saeed, Bo Peng, Kevin Kim, Kavita Rawat, Lindsey M Kuehm, Zoe R Siegel, Ariel Borkowski, Nabih Habib, Brian Andrew Van Tine, Nadeem A Sheikh, Vu Tuyen, Daniel L J Thorek, Todd A Fehniger, Russell K Pachynski
High dimensional analyses reveal IL-15 enhances activation of Sipuleucel-T lymphocyte subsets and reverses immunoresistance. Cancer immunology research (2024)
Muhammad A Saeed, Bo Peng, Kevin Kim, Kavita Rawat, Lindsey M Kuehm, Zoe R Siegel, Ariel Borkowski, Nabih Habib, Brian Andrew Van Tine, Nadeem A Sheikh, Vu Tuyen, Daniel L J Thorek, Todd A Fehniger, Russell K Pachynski
High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance. Cancer immunology research 12 (5) (2024)
Muhammad A Saeed, Bo Peng, Kevin Kim, Kavita Rawat, Lindsey M Kuehm, Zoe R Siegel, Ariel Borkowski, Nabih Habib, Brian Andrew Van Tine, Nadeem A Sheikh, Vu Tuyen, Daniel L J Thorek, Todd A Fehniger, Russell K Pachynski
High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance. Cancer immunology research 12 (5) (2024)
Emmanuel S Antonarakis, Sumit K Subudhi, Christopher M Pieczonka, Lawrence Ivan Karsh, David I Quinn, Jason M Hafron, Helen M Wilfehrt, Matthew Harmon, Nadeem A Sheikh, Neal D Shore, Daniel P Petrylak
Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)